BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

...results suggest the novel mechanism of action, NRF2...
...to prove long-term renal protection.TARGETSNRF2 (NFE2L2) – Nuclear factor...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...Genotype-Tissue Expression program (see “Meta on Data”).TARGETSPARK7 (DJ-1) – Parkinsonism associated deglycaseNF-κB (NFKB1; p105; p50) – Nuclear factor...
...cells 1 BC Staff University of Chicago City of Hope University of Luxembourg Icahn School of Medicine at Mount Sinai NIH CD19 DJ-1 (PARK7) Nuclear factor...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

...all hospitalized patients and up to 72% of those who do not survive COVID-19. The NFE2L2...
...of $1.3 billion. Targets IFNα - Interferon α IFNλ - Interferon λ NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2 Elizabeth...
BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

...SARS-CoV-2 replication in a cell-based assay. Targets IL-6 - Interleukin-6 NF-kB (NFKB1) (p105) (p50) - Nuclear factor...
...de la Recherche Medicale (INSERM) Moleculin Biotech Inc. Chongqing Zhifei Biological Products Co. Ltd. SARS-CoV-2 nucleocapsid protein (SARS-CoV-2 N) Nuclear factor...
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

...Janus kinase MYD88 - Myeloid differentiation primary response gene 88 NF-kB (NFKB1) (p105) (p50) - Nuclear factor...
...beta Interleukin 1 receptor accessory protein (IL1RAP) Interleukin-1 (IL-1) receptor 1 (CD121A) Myeloid differentiation primary response gene 88 (MYD88) Nuclear factor...
BioCentury | Jun 12, 2020
Deals

Reata rebound

...and autosomal dominant polycystic kidney disease 10/10/19 - Reacquires rights to bardoxolone, omaveloxolone and next-generation Nrf2...
...has stretched across a decade. Abbott Laboratories (NYSE:ABT) paid $450 million up front for the NFE2L2...
...2011, and doubled down later that year, paying $400 million up front for Reata’s remaining NFE2L2...
BioCentury | Apr 11, 2020
Translation in Brief

ILIAS Biologics’ exosomes for sepsis; plus regulating cocaine seeking and a new COVID-19 target

...Nuclear factor of k light polypeptide gene enhancer in B cells 1 NFKBIA (IKBA) - Nuclear factor...
...Science and Technology Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha (NFKBIA) Androgen receptor Nuclear factor...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...a proof-of-concept experiment two compounds that displaced a KEAP1-binding peptide derived from the transcription factor NFE2L2...
...proteinase Cas3 - CRISPR-associated helicase Cas3 KEAP1 - Kelch-like ECH-associated protein 1 NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2 BioCentury...
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 NF-kB (NFKB1; p105; p50) - Nuclear factor...
BioCentury | Feb 1, 2020
Finance

Reata rises on renal interest from Amgen

...business development opportunities there.” Reata Pharmaceuticals Inc. (NASDAQ:RETA) regained rights to its first- and second-generation NFE2L2...
Items per page:
1 - 10 of 345